Flomenberg Neal 4
4 · Tevogen Bio Holdings Inc. · Filed Mar 17, 2026
Research Summary
AI-generated summary of this filing
Tevogen (TVGN) Chief Scientific Officer Neal Flomenberg Sells Shares
What Happened
Neal Flomenberg, Tevogen Bio Holdings’ Chief Scientific Officer and Global R&D Lead, reported sales of 972 shares (total proceeds $6,635) in three transactions to satisfy tax withholding on vested restricted stock units. Transactions: 19 shares on 2026-03-10 at $7.75 ($147), 452 shares on 2026-03-11 at a weighted $7.26 ($3,282), and 501 shares on 2026-03-13 at a weighted $6.40 (~$3,206). These were sales (code S) and, per the filing, were made solely to cover tax obligations and not at the reporting person’s discretion.
Key Details
- Transaction dates: 2026-03-10, 2026-03-11, 2026-03-13; Form 4 filed 2026-03-17 (timely).
- Prices and proceeds:
- 19 sh @ $7.75 = $147
- 452 sh @ weighted $7.26 = $3,282 (individual trades ranged $7.25–$7.33 per footnote)
- 501 sh @ weighted $6.40 = $3,206 (individual trades ranged $6.39–$6.74 per footnote)
- Total shares sold: 972; total reported proceeds: ~$6,635.
- Shares owned after the transaction: not specified in the provided excerpt of the filing.
- Notable footnotes: F1 — sales solely to satisfy tax withholding for RSU settlement (not discretionary); F2 — reported prices are weighted averages and detailed per-request; F3/F4 — price ranges for grouped sales.
- Remark/role: Chief Scientific Officer, Global R&D Lead.
- All holdings reported have been adjusted for the 1-for-50 reverse stock split effective March 6, 2026.
Context
These sales were tax-withholding related to RSU settlement (routine, labeled in the filing), which is common and does not necessarily signal a voluntary sell decision. No option exercises, gifts, or 10% owner transactions are indicated. The filing appears timely based on the transaction and filing dates.
Insider Transaction Report
- Sale
Common Stock
[F1]2026-03-10$7.75/sh−19$147→ 77,893 total - Sale
Common Stock
[F1][F2][F3]2026-03-11$7.26/sh−452$3,282→ 77,441 total - Sale
Common Stock
[F1][F2][F4]2026-03-13$6.40/sh−501$3,206→ 76,940 total
Footnotes (4)
- [F1]The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement of restricted stock units. Such sales were not made at the discretion of the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.
- [F3]These shares were sold in multiple transactions at prices ranging from $7.25 to $7.33, inclusive.
- [F4]These shares were sold in multiple transactions at prices ranging from $6.39 to $6.74, inclusive.